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Introduction {#sec1}
============

Human pluripotent stem cells (hPSCs) enable modeling aspects of development and disease, and hold great promise for regenerative medicine and drug discovery ([@bib47], [@bib51]). Previous large-scale analyses of hPSCs shed light on pluripotency, differentiation, and de-differentiation by focusing on transcriptional regulation, epigenetic changes, and non-coding RNAs ([@bib5], [@bib6], [@bib12], [@bib24]). However, proteomes contain vast amounts of biological information unobtainable via genomics, transcriptomics, or similar analyses ([@bib49]). Thus, a detailed characterization of pluripotency, lineage specification, and reprogramming by protein profiling is important for complementing other analytical methods and should help to elucidate novel mechanisms.

Regulation of proteins includes quantitative changes and post-translational modifications (PTMs) ([@bib18]). A key PTM is reversible phosphorylation of serine (pS), threonine (pT), and tyrosine (pY), which modulates enzyme activities, protein-protein interactions, conformational changes, protein half-life, and signal transduction, among others ([@bib10]). Multidimensional liquid chromatography (MDLC) coupled with tandem mass spectrometry (MS/MS) enables large-scale analysis of proteomes and phosphoproteomes ([@bib18], [@bib39]). Although previous reports have provided important insights into the proteomes of hPSCs ([@bib7], [@bib27], [@bib33], [@bib34], [@bib41], [@bib46], [@bib45]), none of these studies have applied robustly controlled differentiation strategies in feeder-free monolayer cultures. Hence, proteomic analysis of pluripotent cells compared with their lineage-specific multipotent derivatives has not been reported. Moreover, previous datasets did not reach the depth enabled by recent technical advances ([@bib18], [@bib39]). Notably, label-free quantification (LFQ) can yield deeper proteome coverage than stable-isotope labeling by amino acids in cell culture while maintaining quantitative accuracy ([@bib11], [@bib14], [@bib39]).

Here, we employed a controlled and reproducible neural induction strategy to investigate the combined proteomic and phosphoproteomic \[termed (phospho)proteomic\] changes that occur when hESCs differentiate to a highly pure population of hNSCs. These experiments also include molecular and electrophysiological characterizations of more differentiated cellular progeny, thereby confirming the multipotency of the hNSCs studied. LFQ proteomic methods allowed elucidation of cell type-specific (phospho)proteomes at an unprecedented depth. To demonstrate the utility of the dataset, we performed systems-level analyses of cell-signaling pathways and protein families, and created a map of epigenetic proteins, many of which are regulated during differentiation. Our dataset includes a large (phospho)proteomics resource of transcription factors (n = 487) including previously unidentified phosphorylation sites on OCT4, NANOG, SOX2, and others. Moreover, to demonstrate the utility of the dataset we performed functional experiments showing that the secreted protein midkine (MDK), which our (phospho)proteomic analyses found to be upregulated during neural commitment, instigates neural specification.

Results {#sec2}
=======

Directed Differentiation of hPSCs to Enable (Phospho)Proteomic Profiling of Neural Lineage Commitment {#sec2.1}
-----------------------------------------------------------------------------------------------------

Pluripotent cells were maintained under feeder-free monolayer conditions. For neural induction, exogenous fibroblast growth factor (FGF2) was omitted from the culture medium and a small-molecule cocktail (termed DAP; [Figure 1](#fig1){ref-type="fig"}A) was added to suppress pathways that otherwise contribute to pluripotency and/or non-neural differentiation of hESCs ([@bib4], [@bib9], [@bib16], [@bib32], [@bib40]). The 6-day DAP treatment that we developed in our laboratory produced highly pure cultures of hNSCs (\>97% PAX6^+^/NESTIN^+^ cells; [Figures 1](#fig1){ref-type="fig"}A and 1B). This neural induction strategy was characterized by demonstrating: inhibition of SMAD phosphorylation sites ([Figure S1](#mmc1){ref-type="supplementary-material"}A); induction of neural markers ([Figures S1](#mmc1){ref-type="supplementary-material"}B, S1D, and S1F); downregulation of pluripotency markers OCT4 and NANOG ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1F); absence of mesoderm (BRACHYURY), endoderm (SOX17), neural crest (SOX10, TFAP2A, SNAI2), and non-neural ectoderm (MSX1/2) ([Figures S1](#mmc1){ref-type="supplementary-material"}F and S1G); comparison with embryoid body (EB) differentiation ([Figure S1](#mmc1){ref-type="supplementary-material"}F); immunostaining for PAX6/OTX2/NESTIN, normal karyotype; and efficient neuralization using human induced PSCs (hiPSCs) ([Figures 1](#fig1){ref-type="fig"}A, [S1](#mmc1){ref-type="supplementary-material"}H, and S1I).

hNSCs expanded in FGF2 for 30 days underwent anterior-to-posterior specification, suggested by induction of *GBX2*, *DACH1*, *HOXA2*, and *HOXB4*, and downregulation of *PAX6*, *PAX7*, *PLZF*, and *OTX1* ([Figure S2](#mmc1){ref-type="supplementary-material"}A), consistent with a previous report ([@bib31]). To demonstrate multipotency, we differentiated hNSCs into more mature cell types representing the three main neural lineages (neurons, astrocytes, and oligodendrocytes; [Figures S2](#mmc1){ref-type="supplementary-material"}B--S2E). Moreover, neuronal activity was measured by electrophysiological analyses. Spontaneous synaptic currents, action potential generation, and ion channel response was observed when inhibitory (GABA) and excitatory (NMDA + glycine) stimuli were applied ([Figure S3](#mmc1){ref-type="supplementary-material"}). Together, these results show that highly pure hNSCs and their more differentiated progeny were obtained from 6-day DAP treatment of hPSCs. Because the (phospho)proteomes of hESCs grown under feeder-free conditions and their earliest definitive neural derivatives expressing PAX6 ([@bib31], [@bib52]) have not been compared previously, we decided to perform this comparative (phospho)proteome analysis.

Total (Phospho)Proteome Analysis Platform {#sec2.2}
-----------------------------------------

(Phospho)proteins were digested to peptides and separated by strong cation exchange chromatography (SCX) ([Figures 1](#fig1){ref-type="fig"}C and [S4](#mmc1){ref-type="supplementary-material"}; [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}). Phosphopeptides were enriched from SCX fractions ([@bib13], [@bib17]) ([Figure 1](#fig1){ref-type="fig"}C). Non-binding and wash fractions (containing primarily non-phosphorylated peptides) and enriched phosphopeptides were subjected to liquid chromatography (LC)-electrospray ionization (ESI)-MS/MS, including optimized LC gradients ([@bib17]). MS/MS data was searched against a human protein database and identifications were filtered at a protein-level false discovery rate (FDR) of \<0.01 and peptide-level FDR of \<0.006 ([Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}). LFQ was by normalized spectral abundance factor (NSAF) spectral counting (SpC) ([@bib21], [@bib53]), using non-phosphopeptides only, to improve quantitative reliability ([Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}). Analysis of protein phosphorylation included identification of phosphopeptides and phosphorylation sites, and calculation of phosphopeptide spectral counts (PSpCs). The PSpC is the number of MS/MS spectra in a replicate that resulted in identification of a phosphopeptide. Identifications employed "precision proteomics" ([@bib10]) and additional high-confidence analyses ([Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}).

Variability of protein identifications was only 8.6%--15.0% between replicates ([Figure 1](#fig1){ref-type="fig"}D). The number of non-redundant phosphorylation sites is presented in [Table S1](#mmc1){ref-type="supplementary-material"}, whereas [Tables S2--S16](#mmc1){ref-type="supplementary-material"} are available at [http://dx.doi.org/10.17632/v7nt3wm8rk.1](10.17632/v7nt3wm8rk.1){#intref0010}. Protein families are presented in [Tables S2--S7](#mmc1){ref-type="supplementary-material"}. Detailed information on all peptide and phosphopeptide identifications is given in [Tables S8--S13](#mmc1){ref-type="supplementary-material"}. Biological data annotation is available at a searchable website, <http://pluriprot.org>. [Figure S5](#mmc1){ref-type="supplementary-material"}A illustrates how to access information on (phospho)proteins from our dataset. Protein network analyses on PluriProt highlight pathways and biological processes enriched in hESCs or hNSCs ([Figure S5](#mmc1){ref-type="supplementary-material"}B).

(Phospho)Proteins Detected in Pluripotent or Multipotent Cells Only {#sec2.3}
-------------------------------------------------------------------

Among the 13.6% of the proteins exclusively detected in hESCs were proteins associated with pluripotency, including ESRRB, UTF1, FOXO1, ALPI (alkaline phosphatase), TERT, and TDGF1 ([Figures 2](#fig2){ref-type="fig"}A, 2B, and 2E; [Tables S14](#mmc1){ref-type="supplementary-material"}A and [S15](#mmc1){ref-type="supplementary-material"}A). In contrast, neural markers such as PAX6, PLZF, SOX5, SOX10, LHX1, SEZ6, and ARX were detected in hNSCs only ([Tables S14](#mmc1){ref-type="supplementary-material"}A and [S15](#mmc1){ref-type="supplementary-material"}B). Notably, 76.4% of all detected proteins were phosphorylated ([Figures 2](#fig2){ref-type="fig"}A and 2B).

Analysis of Protein Abundance {#sec2.4}
-----------------------------

First, a statistical test (t test) for proteomic data ([@bib56]) was used to analyze hESC/hNSC NSAF-SpC ratios (termed E/N ratios). The mean E/N ratio for the dataset was 1.27 and the median was 0.97, providing general support for this approach. Second, the mean E/N ratio of all non-regulated ribosomal proteins in the dataset, 1.13, and the SD (= 0.24; [Table S14](#mmc1){ref-type="supplementary-material"}B) enabled significant difference thresholds of an E/N ratio ≥2.00 or ≤0.50. These thresholds are \>3 SD from the mean, and should translate to ca. p \< 0.01 when the SpC threshold (≥10; clarified below) is met. Third, the natural log (L~n~) of the NSAFs ([@bib56]; [Table S14](#mmc1){ref-type="supplementary-material"}A) of the proteins was plotted ([Figure 2](#fig2){ref-type="fig"}C). Proteins with an E/N ratio differing significantly between hESCs and hNSCs (t test; p \< 0.05) are shown as red, brown, and green dots in [Figure 2](#fig2){ref-type="fig"}C. Proteins expected to be more abundant in hESCs with an E/N ratio ≥2.00 are represented by red dots, whereas brown dots indicate those expected to be more abundant in hNSCs, with an E/N ratio ≤0.50 ([Figure 2](#fig2){ref-type="fig"}C). Green dots represent proteins with 0.50 \< E/N ratio \< 2.00. For example, HSPD1, with a significantly differing E/N ratio (1.56; p = 0.00063) was more abundant in hESCs, whereas LIN28A (E/N ratio = 0.63; p = 0.0020) was more abundant in hNSCs ([Figure 2](#fig2){ref-type="fig"}C). Independent western blot experiments agreed with E/N ratios ([Figure S6](#mmc1){ref-type="supplementary-material"}A). However, in some cases the t test can miss differentially abundant proteins (e.g., CTCF, [Figure S6](#mmc1){ref-type="supplementary-material"}B), consistent with a recent report ([@bib14]). Thus, we propose that proteins with p \> 0.05 but an E/N ratio ≥2.00 or ≤0.50 (above) and SpC ≥10 in hESCs and/or hNSCs (SpC threshold) should provide reliable information on significant differences. False change rates for proteins with SpC ≥10 were \<1% in a previous report ([@bib54]). Accordingly, protein quantification in the dataset demonstrated high reproducibility ([Figure S6](#mmc1){ref-type="supplementary-material"}C). Furthermore, "housekeeping" proteins GAPDH, HPRT1, and α-tubulin (TUBA1C) (E/N ratios of 0.81, 1.10, and 0.94, respectively) displayed similar relative abundance ([pluriprot.org](http://pluriprot.org){#intref0020}), suggesting quantitative reliability.

Using these parameters, we identified protein networks enriched in hESCs, including structural proteins (e.g., cytoskeleton, cell adhesion) and regulatory proteins (e.g., cell cycle, anti-apoptotic; [Figure 2](#fig2){ref-type="fig"}D). Proteins enriched in hNSCs were indicative of chromatin modification, neurogenesis, axonal guidance, cell adhesion, androgen receptor signaling, and microtubules ([Figure 2](#fig2){ref-type="fig"}D).

Transcription Factors: Distinct Protein Abundance and Phosphorylation Profiles in Pluripotent and Lineage-Committed Cells {#sec2.5}
-------------------------------------------------------------------------------------------------------------------------

The dataset contains 487 transcription factors, with 416 identified in hESCs and 419 in hNSCs ([Figure S6](#mmc1){ref-type="supplementary-material"}D), including OCT4, NANOG, and PAX6, which serve as positive controls ([Figures 2](#fig2){ref-type="fig"}C, 2E, [S1](#mmc1){ref-type="supplementary-material"}C--S1F). Some proteins were detected only via phosphopeptides ([Figure 2](#fig2){ref-type="fig"}E, SpC = 0), suggesting enhanced sensitivity for detecting proteins due to phosphopeptide enrichment, consistent with another report ([@bib18]).

Most transcription factors were phosphorylated ([Figures S6](#mmc1){ref-type="supplementary-material"}D and S6E; [Tables S2--S7](#mmc1){ref-type="supplementary-material"}). Differential phosphorylation of a protein includes at least one site detected in hESCs or hNSCs only (e.g., LRRFIP1), detection of phosphorylation in hESCs only (e.g., FOXO1), or detection of phosphorylation in hNSCs only (e.g., ENC1) ([Figure 2](#fig2){ref-type="fig"}E and [Table S15](#mmc1){ref-type="supplementary-material"}). In contrast, some proteins lacked differing phosphorylation sites (e.g., PTTG1). Repeated identification versus lack of identification implies that the phosphopeptide is likely to be more abundant in the cell population in which it was identified ([@bib7]). The PSpC of individual phosphopeptides was between 1 and \>100 ([Figure S6](#mmc1){ref-type="supplementary-material"}F). In addition, pY sites were identified on some transcription factors, e.g., OCT4 ([Figure 2](#fig2){ref-type="fig"}E).

Analysis of Kinases and Phosphorylation Motifs {#sec2.6}
----------------------------------------------

The human genome encodes an estimated 518 protein kinases ([@bib23]), 479 of which (92.5%) were detected in hESCs and hNSCs ([Tables S2--S7](#mmc1){ref-type="supplementary-material"}). Among ∼200 phosphatases encoded by the human genome ([@bib35]), the dataset contains 154 (∼77%); 144 phosphatases were detected in hESCs and 139 in hNSCs.

Receptor tyrosine kinases (RTKs) ERBB2, PDGFR, KDR, and IGF1R promote pluripotency ([@bib7], [@bib48]). Differentially phosphorylated ERBB2 contained 23 detected sites, two of which are pY ([Table S15](#mmc1){ref-type="supplementary-material"}C). IGF1R, KDR, and KIT were more abundant in hESCs ([Table S14](#mmc1){ref-type="supplementary-material"}A) and PDGFR, IGF1R, and KDR contained pY sites ([Tables S15](#mmc1){ref-type="supplementary-material"}A and S15C).

We detected 14 Ephrin RTKs, 13 of which were phosphorylated, four with pY sites ([Figure S6](#mmc1){ref-type="supplementary-material"}G). EPHA4 and EPHB2 contained detected phosphorylation in hNSCs only and were upregulated in hNSCs. Among the five Ephrin ligands that were detected, EFNB1 and EFNB2 were more abundant in hNSCs ([Figure S6](#mmc1){ref-type="supplementary-material"}G). These findings suggest regulation of Ephrin signaling when hESCs transition to hNSCs.

We determined 32 pS sequence motifs in the dataset and predicted S/T kinases in the dataset phosphorylating these motifs ([Figure 3](#fig3){ref-type="fig"}). Heatmap analysis suggests functions for numerous S/T kinases in hESCs and hNSCs, including GSK3α/β, CDKs, MAPK (ERK p38, JNK), AKT, mTOR, and AURKA/B. Phosphorylated AURKA was more abundant in hESCs ([Figures 3](#fig3){ref-type="fig"} and [S6](#mmc1){ref-type="supplementary-material"}B), in agreement with a role of Aurora A in sustaining pluripotency in mouse cells ([@bib20]). Hence, comparative kinome analysis in pluripotent and differentiated cells should enable testing of targeted hypotheses.

Mapping Cell-Signaling Pathways {#sec2.7}
-------------------------------

The dataset allowed identification of 415 biological pathways ([Table S16](#mmc1){ref-type="supplementary-material"}). Transforming growth factor β (TGF-β) and WNT pathways were examined because they are incompletely characterized in pluripotency and early differentiation, and were modulated by the DAP protocol. Coverage of (phospho)proteins in the canonical TGF-β and WNT pathways was 81% and 89%, respectively ([Figures 4](#fig4){ref-type="fig"}A and 4B). Many of these proteins displayed differential abundance and/or phosphorylation. Comparative analysis highlighted (phospho)proteins participating in the regulation of pluripotency and neural conversion (e.g., ID1, LEFTY1, LEFTY2). Additional pathway analyses were performed for Nodal and Notch signaling ([Figures S7](#mmc1){ref-type="supplementary-material"}A and S7B). These examples illustrate that the dataset enables global pathway analysis ([Table S16](#mmc1){ref-type="supplementary-material"}).

Abundance and Phosphorylation of Epigenetic Proteins {#sec2.8}
----------------------------------------------------

Pluripotency is characterized by open chromatin, which is maintained by structural proteins, histone, and DNA modifications that affect gene silencing and activation, whereas lineage commitment of pluripotent cells results in heterochromatin formation ([@bib29], [@bib55]). We reasoned that uniform neural induction is ideal for comparison of the (phospho)proteomic state of epigenetic regulators in pluripotent and multipotent cells. The dataset contains at least 273 proteins involved in epigenetic changes and chromatin modifications ([Figure 5](#fig5){ref-type="fig"}). Eighty-seven percent contained identified phosphorylation, including 33% with pY sites ([Figure 5](#fig5){ref-type="fig"}, magenta circles).

Previous epigenetic protein characterizations were performed mostly in rodent models. The Polycomb repressive complex 2 (PRC2), containing SUZ12, EZH2, and EED, plays an important role in establishing "bivalent domains" in pluripotent cells that keep developmental genes silent but poised for expression upon differentiation ([@bib51]). All PRC2 proteins were phosphorylated in hESCs, and EZH2 and EED were phosphorylated in hNSCs ([Figure 5](#fig5){ref-type="fig"} and [Table S15](#mmc1){ref-type="supplementary-material"}B). The relative abundance of these proteins was similar to changes described during mouse development ([@bib25]). SUZ12 and EZH2 were more abundant in hESCs, whereas EED was more abundant in hNSCs. Other examples of epigenetic regulators are DNMT3B, JARID2, and CHD1, which were more abundant and phosphorylated in hESCs (e.g., pY404 on DNMT3B; pY225 on CHD1).

Non-histone, chromatin-associated high-mobility group (HMG) proteins participate in transcriptional regulation and changes in DNA conformation ([@bib3]). The dataset contains 11 HMG proteins, with HMGB2 upregulated in hNSCs ([Figure S6](#mmc1){ref-type="supplementary-material"}B). Neuronal differentiation is initiated by overcoming the repression by REST, thereby inducing neural-specific genes in mouse cells ([@bib3]). Consistently, REST was downregulated in hNSCs ([Figure 2](#fig2){ref-type="fig"}E). The chromatin insulator CTCF is a key genome organizer that can block the interaction of enhancer elements with unrelated promoters in mouse cells ([@bib15]). CTCF was more abundant in hNSCs, as measured by MDLC-MS/MS and western blots ([Figures 5](#fig5){ref-type="fig"} and [S6](#mmc1){ref-type="supplementary-material"}B). The heterochromatin protein HP1BP3 was upregulated in hNSCs ([www.pluriprot.org](http://www.pluriprot.org){#intref0025}).

Validation of (Phospho)Proteomic Data Suggest a Functional Role for MDK During Neural Differentiation {#sec2.9}
-----------------------------------------------------------------------------------------------------

Although progress has been made ([@bib4], [@bib9]), our understanding of the mechanisms of neural fate choice from hESCs remains incomplete. Since secreted proteins may contribute to cell differentiation, we focused on protein ligands present in our dataset ([Tables S2--S7](#mmc1){ref-type="supplementary-material"}). Among these, MDK was strongly upregulated in hNSCs ([Figure 2](#fig2){ref-type="fig"}C). *MDK* was identified in differentiating teratocarcinoma cells and is expressed in the mouse neural tube during mid-gestation ([@bib28], [@bib44]). Although MDK was detected in the secretome of hESCs ([@bib1]), its functional role has not been studied in hPSCs. MDK is expressed by undifferentiated hPSCs and upregulated when hESCs and hiPSCs are differentiated using the EB method or controlled 6-day DAP treatment ([Figures 6](#fig6){ref-type="fig"}A and 6B). Upregulation of MDK in hNSCs ([Figure 2](#fig2){ref-type="fig"}C) was confirmed by western blots ([Figure 6](#fig6){ref-type="fig"}B). MDK was absent from skin fibroblasts (FB) but induced during cellular reprogramming (FB-hiPSC).

We asked whether inhibition of MDK signaling by an anti-MDK monoclonal antibody has functional consequences for pluripotency and/or neural differentiation. hESCs were cultured in the presence of anti-MDK or isotype control antibody. Anti-MDK did not detectably affect pluripotent growth of hESCs, as measured by alkaline phosphatase staining and expression of OCT4 and NANOG ([Figures 6](#fig6){ref-type="fig"}C and 6D). However, when anti-MDK was applied during 6-day neural induction, upregulation of *OTX1*, *PAX6*, and *PLZF* mRNAs was impaired ([Figure 6](#fig6){ref-type="fig"}E) and neural protein expression was strongly suppressed ([Figures 6](#fig6){ref-type="fig"}F and 6G). We also tested whether MDK promotes mesodermal and endodermal lineage commitment. Experiments using recombinant MDK alone or in combination with the DAP cocktail demonstrated that non-neural markers SOX17, BRACHYURY, and MIXL1 were not induced by MDK but detected in controls treated with fetal bovine serum ([Figure 6](#fig6){ref-type="fig"}H). Furthermore, MDK alone partially induced expression of PAX6 in hESCs but, remarkably, MDK in combination with DAP resulted in earlier and stronger expression of PAX6 compared with DAP treatment alone ([Figure 6](#fig6){ref-type="fig"}H).

Genetic Knockdown of MDK Efficiently Blocks Neural Conversion of Pluripotent Human Cells {#sec2.10}
----------------------------------------------------------------------------------------

To validate that increased MDK expression is important for neural induction, we performed knockdown of *MDK* in hESCs using retroviral short hairpin RNAs (shRNAs). Four stable cell lines with scrambled control shRNA and two cell lines with efficient MDK knockdown were analyzed by western blotting and immunocytochemistry ([Figures 7](#fig7){ref-type="fig"}A--7C). We did not detect differences in self-renewal when hESC lines with scrambled control shRNA or MDK knockdown were expanded in parallel with parental hESCs, similar to the use of anti-MDK antibodies ([Figures 6](#fig6){ref-type="fig"}C and 6D). However, when hESCs were treated with DAP for 6 days, PAX6 expression was blocked in both cell lines with MDK knockdown but not in scrambled shRNA controls ([Figures 7](#fig7){ref-type="fig"}A--7D). These findings, together with experiments using the anti-MDK antibody ([Figures 6](#fig6){ref-type="fig"}E--6G), support the notion that upregulation of MDK is necessary for neural lineage entry of hESCs. Collectively, these results suggest that suppression of TGF-β, bone morphogenetic protein (BMP), and WNT signaling (the rationale for using the DAP cocktail) and the action of autocrine/paracrine MDK are important mechanisms of early neural specification ([Figures 4](#fig4){ref-type="fig"}, [6](#fig6){ref-type="fig"}, and [7](#fig7){ref-type="fig"}).

Complementary Analysis of Neural Induction by Transcriptomic and Proteomic Datasets {#sec2.11}
-----------------------------------------------------------------------------------

Transcriptomic data from the same well-defined cell populations was obtained to gain additional insights into gene regulation in pluripotent and multipotent cells. Among the 9,635 genes whose products were identified as mRNAs and proteins, changes in the relative abundance of cognate mRNAs and proteins displayed concordance and discordance ([Figure S7](#mmc1){ref-type="supplementary-material"}C). Overall correlation in changes between both datasets was only r = 0.40. This may reflect the importance of protein translation, stability, and PTMs as part of the regulatory mechanisms that are integrated with epigenetic and transcriptional changes during the switch of cellular identities. The complexity of these coordinated events has been reported in murine ESCs ([@bib22], [@bib37]). Hence, combined analysis of proteomic and transcriptomic data is desirable for precise characterization of cell type identities during differentiation and reprogramming ([@bib2]). The use of both methods allowed the identification of a larger number of significant biological processes than either alone. Cell type-specific biological processes segregated more clearly when using the proteomic dataset ([Figures 2](#fig2){ref-type="fig"}D and [S7](#mmc1){ref-type="supplementary-material"}D).

Discussion {#sec3}
==========

To our knowledge, uniformly differentiated, lineage-committed cells derived from hESCs have not been analyzed previously by proteomics. Our data provided insights into the molecular complexity of pluripotency and cell differentiation, and captured specific (phospho)proteomic signatures in direct comparisons of hESCs and hNSCs. The data shed light on cell-signaling pathways and the human kinome, and established an expanded resource of epigenetic proteins.

The dataset allows a well-defined comparison of protein abundance and phosphorylation in pluripotent cells and the earliest definitive hNSCs. This contrasts with previous studies that used hESCs and heterogeneous mixtures of differentiated progeny ([@bib7], [@bib34], [@bib46]), or hESCs only ([@bib41]). Another study compared hESCs and hiPSCs, reporting 6,761 proteins and 19,122 phosphorylation sites ([@bib33]). A proteomic analysis of the membrane fraction of hESCs and heterogeneous cells enriched for NSCs, derived by EB differentiation, yielded 5,105 proteins and 8,560 phosphorylation sites ([@bib26]). In contrast, we used whole-cell lysates from hESCs and their hNSC derivatives at high purity under feeder-free conditions. Importantly, we did not passage the cells during hNSC induction, so as to capture unperturbed (phospho)proteomic profiles when pluripotent cells transition to the neural lineage. We report nearly 13,000 proteins ([Figure 2](#fig2){ref-type="fig"}A), most of which were phosphorylated at nearly 60,000 non-redundant sites ([Table S1](#mmc1){ref-type="supplementary-material"}), revealing a striking depth of (phospho)proteomes and biological pathways. The dataset contains most previously published (phospho)proteins in hPSCs, plus more not reported in those studies ([Figures S7](#mmc1){ref-type="supplementary-material"}E--S7H). In addition, our results suggest previously unknown reproducibility of the hPSC phosphoproteome via comparison with these datasets.

Phosphorylated transcription factors are prominent in hESCs ([@bib7], [@bib34], [@bib46]). Our current dataset represents progress toward comprehensive (phospho)proteomic mapping of transcription factors. [@bib34] found that 83.8% of 216 detected transcription factors were phosphorylated. Similarly, 75.1% of the 487 transcription factors in our dataset were phosphorylated. OCT4 phosphorylation on pT234 and pS235 disrupts its binding to DNA ([@bib8]). Phosphorylation sites pT225 and pY291 ([Table S15](#mmc1){ref-type="supplementary-material"}A), to the best of our knowledge, have not been identified previously on OCT4. Our dataset also contains two phosphorylation sites on NANOG (pS10 and pS52). In addition, 12 phosphorylation sites were detected on SOX2, five of which were not reported previously (pY2, pT7, pT17 or pS18, pS257, and pS290). These and other examples suggest the importance of post-translational regulation of transcription factors, which is understudied.

Dual SMAD inhibition and modulation of WNT signaling is important for neural conversion of hPSCs, as indicated previously ([@bib9], [@bib16]) and by the present study ([Figure 1](#fig1){ref-type="fig"}A). NPTX1 plays a role in neural lineage specification from hESCs by reducing NODAL and BMP signaling ([@bib4]), suggesting that NPTX1 further contributes to dual SMAD inhibition ([@bib9]). However, it remained unclear whether neural induction is regulated by other signals. The secreted protein MDK is an instructive component of neural lineage entry ([Figure 7](#fig7){ref-type="fig"}E). Blocking MDK by genetic knockdown and a monoclonal antibody provided independent evidence for a mechanism by which feedforward upregulation of MDK promotes neural induction, consistent with MDK resulting in specific upregulation of PAX6 ([Figures 6](#fig6){ref-type="fig"} and [7](#fig7){ref-type="fig"}). MDK may act through a receptor complex that can include ALK, PTPRZ1, LRP1, and SDC1 ([@bib19], [@bib28]). PTPRZ1 was more abundant in hESCs, whereas LRP1 was more abundant in hNSCs ([Figure 7](#fig7){ref-type="fig"}E). Although *MDK* was reported 26 years ago ([@bib43]), MDK and its receptors remain understudied. Hence, the finding that MDK plays a role in PSC differentiation requires detailed follow-up studies.

Collectively, our methods and dataset are resources to leverage diverse studies including further elucidation of pluripotency, differentiation, and reprogramming. The dataset may also prove useful for comparison with stem cells from non-mammalian models. For example, orthologs of all proteins in the COP9 complex in *Drosophila* germline stem cells ([@bib30]) are in our dataset. We highlighted several analyses that the dataset enables and provided proof of principle for its predictive value. We make this resource freely available to the scientific community as curated tables, an interactive website ([www.pluriprot.org](http://www.pluriprot.org){#intref0030}), and raw data in the Peptide Atlas database (Institute for Systems Biology).

Experimental Procedures {#sec4}
=======================

Cell Culture {#sec4.1}
------------

Pluripotent cells were cultured under feeder-free conditions on Matrigel with MEF-CM and FGF2. For neural induction, unconditioned medium and 2 μM dorsomorphin, 2 μM A83-01, and 2 μM PNU-74654 (DAP cocktail) were added. A retrovirus-based protocol ([@bib42]) was modified to generate hiPSCs. Details are provided in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Immunocytochemistry, Fluorescence-Activated Cell Sorting, and Western Blots {#sec4.2}
---------------------------------------------------------------------------

For immunocytochemistry, cells were fixed in 4% paraformaldehyde and stained with the antibodies listed in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. Fluorescence-activated cell sorting analysis ([@bib31]) and western blots ([@bib7]) were as described previously. Details, including procedures for immunoprecipitations, are provided in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Knockdown of MDK by shRNA {#sec4.3}
-------------------------

hESCs were transduced with either MDK or scrambled control shRNA, and drug selection with puromycin and kanamycin was used to establish stable cell lines.

MDK Inhibition by a Monoclonal Antibody {#sec4.4}
---------------------------------------

Medium with either anti-MDK or isotype control antibodies was added daily with the DAP cocktail for 6 days.

Transcriptome Analysis {#sec4.5}
----------------------

Illumina HumanHT-12 Expression Arrays were analyzed using a BeadArray Reader. Data were collected using the scanner software. Sample probe files were obtained using GenomeStudio after expression intensities were calculated and quality controlled with detection p values of ≤0.05 for each gene probe. Differentially expressed genes were detected in GeneSpring GX 11.5 by quantile normalization, log transformation, t tests with Benjamini-Hochberg corrected p value of ≤0.05, and fold-change difference of ≥2.0.

Total (Phospho)Proteome Work Flow {#sec4.6}
---------------------------------

Approximately 4 × 10^7^ hESCs or hNSCs were rinsed with PBS and lysed. Lysates were centrifuged, (NH~4~)~2~SO~4~ added to supernatants, mixtures agitated at 4°C, and centrifuged. Protein pellets were stored at −80°C. Pellets were resuspended in 100 mM (NH~4~)~2~HCO~3~/8 M urea containing protease and phosphatase inhibitors and gel filtered, and protein concentrations measured. Protein (1 mg) was reduced, alkylated, digested with trypsin, peptides desalted, dried, and stored at −80°C.

Peptides were separated by SCX, desalted, and dried. Phosphopeptides were enriched from SCX fractions. LC-ESI-MS/MS was performed on each fraction in duplicate with a C18 column, captive spray source, and LTQ Orbitrap Velos mass spectrometer with electron-transfer dissociation.

MS/MS data were searched against a concatenated forward and reverse ipi.HUMAN.v.3.73 database with Sorcerer-SEQUEST. Static carbamidomethylation of C, differential oxidation of M, and differential phosphorylation of S, T, and Y were specified. Protein identifications were filtered at an FDR of \<0.01 (ProteinProphet), including stringent phosphopeptide-level verification ([Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}). NSAF-SpCs ([@bib53]), Ln-NSAFs ([@bib56]), and PSpCs were calculated.

(Phospho)Proteomic Data Mining {#sec4.7}
------------------------------

Cell-signaling pathways, protein networks, and interaction maps were analyzed and processed using KEGG, Ingenuity, GeneGO, Cytoscape, and Adobe Photoshop. Phosphorylation motifs and kinase predictions were as described previously ([@bib38], [@bib50]) and displayed with Treeview ([@bib36]), and predicted kinases not in the dataset were removed ([Figure 3](#fig3){ref-type="fig"}).

Supplemental Material {#sec4.8}
---------------------

[Table S1](#mmc1){ref-type="supplementary-material"} is included in the [Supplemental Information](#app3){ref-type="sec"}, and [Tables S2--S16](#mmc1){ref-type="supplementary-material"} can be downloaded at [http://dx.doi.org/10.17632/v7nt3wm8rk.1](10.17632/v7nt3wm8rk.1){#intref0035}. Interactive analysis of the proteomic dataset can be performed by searching for specific proteins of interest (enter protein name on Homepage) and accessing Network diagrams (Networks): <http://pluriprot.org>.

Source Data {#sec4.9}
-----------

[Tables S2--S16](#mmc1){ref-type="supplementary-material"}: [http://dx.doi.org/10.17632/v7nt3wm8rk.1](10.17632/v7nt3wm8rk.1){#intref0045}.

Author Contributions {#sec5}
====================

Concept and experimental design: I.S., J.H., and L.M.B; Experiments performed: I.S., A.M.C., J.H., B.T.D.T., M.T., A.A.W., J.C., E.L., G.J.G., and L.M.B.; Data analysis and discussions: I.S., J.H., K.S.D., X.H., D.M.H., D.A.W., S.A.L., G.J.G., E.Y.S., and L.M.B.; Manuscript writing: I.S., G.J.G., and L.M.B.

Accession Numbers {#app1}
=================

The (phospho)proteome data can be accessed on the websites specified above, and all raw data are deposited in the Peptide Atlas (accession number PASS00233; <https://db.systemsbiology.net/sbeams/cgi/PeptideAtlas/PASS_View?identifier=PASS00233>; Institute for Systems Biology).

Transcriptomic data are in the Gene Expression Omnibus, accession number GEO: [GSE39876](ncbi-geo:GSE39876){#intref0055}.
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![Controlled Neural Induction and Schematic Diagram of the (Phospho)Proteomic Workflow to Compare Human Pluripotency and Neural Multipotency\
(A) Experimental approach for efficient 6-day neural conversion of hESCs into hNSCs using dorsomorphin, A83-01, and PNU-74654 (termed DAP cocktail). Scale bars represent 100 μm.\
(B) Fluorescence-activated cell sorting suggests virtually uniform conversion of hPSCs to PAX6^+^/NESTIN^+^ (NES^+^) hNSCs.\
(C) Schematic diagram of the workflow for total (phospho)proteome analysis. Fr, fraction; RP, reversed-phase; LC, liquid chromatography; ESI, electrospray ionization; LFQ, label-free quantification. "Precision proteomics" yields accurate results ([@bib10]).\
(D) Reproducibility of protein identification and quantification among experimental replicates was high.\
See also [Figures S1--S6](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![Comparative Analysis of (Phospho)Proteomes of Pluripotent hESCs and Multipotent hNSCs\
(A and B) Venn diagrams illustrating identification of all proteins, termed the (phospho)proteome and phosphorylated proteins in hESCs (red; left portion of each diagram), hNSCs (brown; right portion of each diagram), and both cell populations (gray; overlap).\
(C) Proteins with significantly differing relative abundance (t test, three replicates; p ≤ 0.05) are represented as red, green, or brown dots, whereas gray dots represent proteins with p \> 0.05. Ln~NSAF~ is the mean natural log of the normalized spectral abundance factor (NSAF) for the protein in either hESCs ([Table S14](#mmc1){ref-type="supplementary-material"}, column J) or hNSCs ([Table S14](#mmc1){ref-type="supplementary-material"}, column M).\
(D) Process network analysis using differentially abundant proteins suggests distinctions in biological mechanisms between hESCs and hNSCs. Network significance is shown by red bars (hESCs) or brown bars (hNSCs).\
(E) Transcription factors more abundant in hESCs (red font; left panel), hNSCs (brown font; right panel), or without detected differences in abundance (gray font; middle panel). SpC designates total spectral counts for the protein in both cell populations; 7^∗^ designates that NANOG p = 0.00029 (three replicates, t test; [Table S14](#mmc1){ref-type="supplementary-material"}A). N/A, not applicable. The number of localized pY sites (\# of pY) and total number of phosphorylation sites (total \#p) are shown. Blue superscripts represent phosphorylation detection in hESCs only. Superscripts for proteins with phosphorylation in hESCs and hNSCs are in gold when ≥1 phosphorylation site detection on the protein differed between hESCs and hNSCs; otherwise superscripts are in gray. Green superscripts represent phosphorylation detection in hNSCs only.\
See also [Figures S6](#mmc1){ref-type="supplementary-material"} and [S7](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![S/T Kinases and Their Predicted Substrate Motifs\
Motif-X ([@bib38]) was used to compute phosphopeptide sequence motifs from localized pS sites. The occurrence of motifs is represented by bar graphs at the top (red, hESCs only; brown, hNSCs only; gray, both cell types). GPS 2.0 ([@bib50]) was used to predict and classify kinases (left) phosphorylating the pS motifs. The colors of kinase symbols (representative of relative abundance) and superscripts (representative of phosphorylation) are defined in [Figure 2](#fig2){ref-type="fig"}E. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

![Mapping TGF-β and WNT pathways in hESCs and hNSCs\
(Phospho)proteomic data revealed most components of the canonical TGF-β (A) and WNT (B) signaling pathways. Proteins more abundant in hESCs are in red and those more abundant in hNSCs in brown. Proteins without detected differences in abundance are in gray. Proteins not detected are in white. Numbers adjacent to the proteins indicate the E/N ratio. Circles represent protein phosphorylation, with the same colors as the superscript font in [Figure 2](#fig2){ref-type="fig"}E. Magenta bands represent ≥1 pY site. Larger circles represent proteins with larger numbers of non-redundant phosphorylation sites. Seven TCF and 14 PRKA proteins were detected (B), respectively ([Tables S15](#mmc1){ref-type="supplementary-material"}A--S15C; for clarity, TCF and PRKA phosphorylation is not shown). See also [Figure S7](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}

![(Phospho)Proteome of Epigenetic Regulators in hESCs and hNSCs\
Proteins represented as circles were phosphorylated, whereas triangles represent proteins lacking identified phosphorylation (P and NP, respectively). Red or brown represents higher relative protein abundance in hESCs or hNSCs, respectively. Gray indicates that no significant difference in the abundance of the protein was detected. Numbers indicate the E/N ratio. Colors of circular bands indicate comparative phosphorylation between cell types as described for [Figures 2](#fig2){ref-type="fig"}E and [4](#fig4){ref-type="fig"}. Symbols of proteins in bold font are mentioned in the text. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.](gr5){#fig5}

![MDK Expression in Pluripotent and Differentiated Cells and Disruption of Neural Conversion by a Monoclonal Antibody against MDK\
(A) Representative immunocytochemical analysis of MDK expression by hESCs (WA09), skin fibroblasts (FB, line HS27), and fibroblasts (HS27) after reprogramming to hiPSCs. Scale bars represent 100 μm.\
(B) Western blot showing that MDK was not detected in HS27 fibroblasts but was expressed in WA09 hESCs and hiPSCs from HS27 fibroblasts, and was upregulated in differentiating cells (EBs and hNSCs from hESCs). Probing for GAPDH demonstrated similar loading of the lanes.\
(C) A monoclonal antibody against MDK did not impair pluripotent self-renewal of hESCs. Antibody concentrations are shown.\
(D) The percentage of pluripotent cells expressing OCT4 and NANOG did not differ significantly between anti-MDK and isotype control antibody treatment (3.0 μg/mL). Error bars represent SEM; n = 5.\
(E) qRT-PCR showed that a monoclonal antibody against MDK (1.5 μg/mL) inhibits neural gene expression during 6-day DAP treatment. Error bars represent mean + SEM, n = 3. ^∗^p \< 0.05.\
(F) Western blot analysis confirmed the inhibitory effect of anti-MDK on early neural marker expression (OTX1, PAX6), despite DAP treatment, in contrast to the isotype control.\
(G) Immunocytochemical evidence that neural conversion is inhibited by the anti-MDK antibody (1.5 μg/mL) during 6-day DAP treatment. Few cells induced PAX6 expression in the presence of anti-MDK antibody (right panel). Scale bar represents 200 μm.\
(H) Western blot analysis and time course of hESCs differentiated for 6 days with recombinant MDK alone (100 ng/mL) or a combination of the DAP cocktail and MDK (25 or 100 ng/mL) suggest that MDK specifically promotes neural commitment of hPSCs. SOX17, MIXL1, and Brachyury were not induced by MDK. In contrast, controls treated with fetal bovine serum (FBS) for 6 days, which stimulates multi-lineage differentiation of hPSCs, induced these non-neural markers.](gr6){#fig6}

![MDK Knockdown Validates the Importance of MDK Upregulation for Neural Fate Specification of hESCs\
(A) Western blot analysis of MDK in control H9-hESC lines (scrambled shRNA) and H9-hESC lines with MDK knockdown (left panel). Quantification (right panel) confirmed efficient MDK knockdown.\
(B and C) Immunocytochemical analysis of MDK in control hESCs (scrambled shRNA) (B) and hESCs with MDK shRNA (C) confirmed efficient MDK suppression in the cells containing MDK shRNA. Scale bars represent 100 μm.\
(D) Controls and cell lines with MDK knockdown were treated with DAP for 6 days. PAX6 was inhibited in cell lines with MDK knockdown, whereas PAX6 was expressed in scrambled shRNA controls.\
(E) Model proposed for controlled neural induction of hESCs, depicting the simultaneous modulation of cell-signaling pathways and a role for MDK. The (phospho)proteomic dataset also suggests changes in relative abundance and phosphorylation of putative MDK receptors (ALK, PTPRZ1, SDC1, and LRP1) in hESCs and hNSCs. Colors are as described in [Figure 2](#fig2){ref-type="fig"}E and the sizes of letters reflect E/N and PSpC ratios.](gr7){#fig7}
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